CIK 0000882095
- Large accelerated filer
GILEAD SCIENCES, INC.
Sign in to watch- Ticker
- GILD
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 943047598
- Phone
- +1 650-574-3000
- Business address
- 333 LAKESIDE DR, FOSTER CITY, CA, 94404
- Former names
- GILEAD SCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $42,286,034
- in 14 filings, $42.3M under 10b5-1 plans
Net −$42,286,034. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-10 | Patterson Sandra SVP, Controllership | Exercise or conversion · Restricted Stock Unit | −1,952 | 9,875 | ||
| 2025-03-10 | Berger Dietmar Chief Medical Officer | Grant or award · Restricted Stock Unit | +8,530 | 57,505 | ||
| 2025-03-10 | Berger Dietmar Chief Medical Officer | Grant or award · Non-qualified Stock Option (Right to Buy) | +37,710 | 37,710 | ||
| 2025-02-18 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −2,500 | $104.09 | $260K | 169,061 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion 10b5-1 | +77,691 | $63.91 | $5.0M | 248,914 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion 10b5-1 | +26,175 | $57.92 | $1.5M | 275,089 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion 10b5-1 | +15,600 | $80.72 | $1.3M | 290,689 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion 10b5-1 | +18,210 | $83.49 | $1.5M | 308,899 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Sale 10b5-1 | −137,676 | $102.22 | $14.1M | 171,223 |
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −77,691 | 17,929 | ||
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −26,175 | 78,515 | ||
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −15,600 | 0 | ||
| 2025-02-12 | Dickinson Andrew D Chief Financial Officer | Exercise or conversion · Non-qualified Stock Option (Right to Buy) 10b5-1 | −18,210 | 0 | ||
| 2025-02-04 | Patterson Sandra SVP, Controllership | Grant or award | +709 | 37,787 | ||
| 2025-02-04 | Telman Deborah H EVP, Corporate Affairs & GC | Grant or award | +12,371 | 34,011 | ||
| 2025-02-04 | O'Day Daniel Patrick Chairman & CEO | Grant or award | +60,031 | 561,559 | ||
| 2025-02-04 | O'Day Daniel Patrick Chairman & CEO | Grant or award | +164,473 | 726,032 | ||
| 2025-02-04 | O'Day Daniel Patrick Chairman & CEO | Shares withheld for taxes | −108,156 | $97.99 | $10.6M | 617,876 |
| 2025-02-04 | Mercier Johanna Chief Commercial Officer | Grant or award | +19,793 | 94,933 | ||
| 2025-02-04 | Mercier Johanna Chief Commercial Officer | Grant or award | +70,712 | 165,645 |
Page 20 of 43 · 857 trades